This Phase II project aims at further advancing and commercializing a microarray-based screening approach, for discovering nucleic acid probes that have high affinity and high specificity for protein and cellular targets. Oligonucleotides discovered in these screens can be engineered into sensors having exquisite sensitivity and selectivity for drug development, environmental sensing and POC-diagnostics;areas currently dominated by antibody based technologies. In Phase II we plan to pursue protein targets that are relevant to each of these market segments, in an effort streamline the commercialization process and establish a broad product portfolio.

Public Health Relevance

The Combigen screening process being further developed in this phase II project will create molecular probes that specifically bind protein based targets. These probes will find applications in environmental sensing, point-of-care diagnostics and drug therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44GM076811-03
Application #
7618630
Study Section
Special Emphasis Panel (ZRG1-BCMB-L (11))
Program Officer
Edmonds, Charles G
Project Start
2006-08-01
Project End
2011-01-30
Budget Start
2009-05-01
Budget End
2011-01-30
Support Year
3
Fiscal Year
2009
Total Cost
$327,591
Indirect Cost
Name
Orthosystems, Inc.
Department
Type
DUNS #
138843722
City
Syracuse
State
NY
Country
United States
Zip Code
13205
Mohammad, Mohammad M; Iyer, Raghuvaran; Howard, Khalil R et al. (2012) Engineering a rigid protein tunnel for biomolecular detection. J Am Chem Soc 134:9521-31